WO/2023/118335 | MOBILE TRANSPORT DEVICE FOR TRANSPORTING INSECT LARVAE |
JP2000041531 | CONTROL OF INSECT PEST WITH TADPOLE SHRIMP |
JP2011103816 | TRANSGENIC SILKWORM |
JOUBERT ALBERT (AU)
GILLES JEREMIE (AU)
US9090911B2 | 2015-07-28 | |||
US7868222B1 | 2011-01-11 | |||
FR2583256A1 | 1986-12-19 |
ROSS, P.A. ET AL.: "Costs of Three Wolbachia Infections on the Survival of Aedes aegypti Larvae under Starvation Conditions", PLOS NEGLECTED TROPICAL DISEASES, vol. 10, no. 1, 2016, pages 1/22 - 22/22, XP055527415
"FAQs I Eliminate Dengue", A NATURAL METHOD TO REDUCE THE SPREAD OF DENGUE, 13 December 2017 (2017-12-13), Retrieved from the Internet
TRICHOSAFE® CAPSULES, 22 November 2016 (2016-11-22), Retrieved from the Internet
CLAIMS 1. A mosquito egg capsule which comprises: a closed capsule; a filler; and a plurality of mosquito eggs; wherein the filler optionally comprises a food source for the mosquito eggs when hatched. 2. The mosquito egg capsule of Claim 1 wherein the filler comprises said food source and activated charcoal. 3. A method of producing a mosquito egg capsule including the steps of: combining a plurality of mosquito eggs and a filler that optionally comprises a food source for the mosquito eggs when hatched; locating at least a portion of the combined mosquito eggs and filler into one or a plurality of capsules; and closing each of the capsules. 4. The method of Claim 3 wherein the filler comprises said food source and activated charcoal. 5. The method of Claim 4, which includes the step of batch preparing the food source, activated charcoal and eggs as a mixture and delivering the mixture to each of said plurality of capsules. 6. A mosquito egg capsule produced by the method of any one of Claims 3- 5. 7. The mosquito egg capsule of Claim 1 or Claim 2 or the method of Claim 3, wherein the capsule comprises a cellulosic polymer such as hydroxypropyl methyl cellulose or hydroxy ethyl methyl cellulose. 8. A method of producing mosquitoes including the step of providing one or a plurality of mosquito egg capsules of Claim 1 , Claim 2 or Claim 6, or mosquitoes produced therefrom, into an environoment under conditions that facilitate hatching of the mosquito eggs into mosquito larvae. 9. The method of Claim 8, wherein the environment is an artificial mosquito rearing system. 10. The method of Claim 8, wherein the environment is a natural environment. 1 1. A method of modifying a mosquito population, including the step of introducing one or a plurality of the mosquito egg capsules according to Claim 1, Claim 2 or Claim 6, or mosquitoes produced therefrom, into an environment under conditions that facilitate hatching of mosquito eggs into mosquito larvae, wherein release of the mosquito larvae into the environment modifies one or more biological properties of said mosquito population. 12. The method of Claim 1 1, wherein the mosquitoes are wild-type or otherwise naturally-occurring mosquitoes that exist in a local environment, region or habitat. 13. The mosquito egg capsule of Claim 1, Claim 2 or Claim 6, or the method of Claim 3 or Claim 8, wherein the mosquito eggs have been modified to produce moquitoes for use as a biocontrol agent in said environment. 14. The mosquito egg capsule or the method of Claim 13, wherein the mosquito eggs are infected with or otherwise comprise a mosquito- adapted bacterium capable of modifying one or more biological properties of a mosquito, wherein said mosquito-adapted bacterium does not normally colonize, inhabit, reside in, or infect said mosquito host. 15. The mosquito egg capsule or the method of Claim 14, wherein the mosquito-adapted bacterium is of the genus Wolbachia. 16. The mosquito egg capsule or the method of Claim 15, wherein said isolated mosquito-adapted bacterium is of the species Wolbachia pipientis. 17. The mosquito egg capsule or the method of Claim 16, wherein said isolated mosquito-adapted bacterium is wMel or wMelCS. |
MOSQUITO EGG CAPSULE FIELD OF THE INVENTION THIS INVENTION relates to environmental control of mosquito-transmitted diseases. More particularly, this invention relates to capsule for storing, hatching and/or rearing mosquitoes for introduction into an environment to act as an agent for biocontrol of diseases transmitted by mosquitoes.
BACKGROUND OF THE INVENTION
Mosquitoes are a source of, or transmit, many diseases and conditions in humans and other animals. Mosquitos are responsible for the transmission of disease-causing pathogens such as arboviruses, flaviviruses and protozoa. These disease-causing pathogens are responsible for a variety of different diseases of humans and other animals including malaria, Dengue fever, Eastern Equine encephalitis, Western Equine encephalitis, Venezuelan equine encephalitis, Japanese encephalitis, Murray Valley encephalitis, West Nile fever, Yellow fever, LaCrosse encephalitis, Asian spotted fever, Q fever, Chikungunya fever, Zika fever and Ross river fever. More recently, in addition to Zika fever, Zika virus has been identified as capable of causing microencephaly and Guillain-Barre syndrome in humans.
In recent years, there has been a resurgence in developing sustainable disease control strategies that target the mosquito host. These include sterile insect techniques, (SIT) and Release of Insects with Dominant Lethality (RIDL). A different and particularly successful strategy has employed a strain of the obligate intracellular bacterium Wolbachia pipientis, wMelPop to target mosquitoes such as Aedes egyptii. Wolbachia are maternally- inherited bacteria that use mechanisms such as cytoplasmic incompatibility (CI), a type of embryonic lethality that results from crosses between infected males with uninfected females, to rapidly spread into insect populations (Hoffmann & Turelli, 1997, S. L. O'Neill, A. A. Hoffmann, J. H. Werren, Eds. (Oxford University Press, Oxford, UK), pp. 42-80).
Such life- shortening Wolbachia strains do not naturally occur in mosquitoes, but have been developed in vitro to become able to infect mosquitoes such as Aedes aegypti. As originally described in United States Patent 9090911 and in McMeniman et al., 2009, supra, Wolbachia pipientis-infected mosquitoes have a shorter life-span, reduced fecundity, altered feeding behaviour, redcued pathogen transmission and/or a lower susceptibility to flavivirus pathogens such as Dengue virus. As more recently described, Wolbachia pipientis-infected Aedes aegypti mosquitoes displayed lower Chikungunya virus and Zika virus prevalence and intensity, decreased disseminated infection and blocked viral transmission (Aliota et al. 2016 PLoS Negl Trop Dis 10 e0004677; Dutra et al., 2016, Cell Host & Microbe 19 771).
SUMMARY OF THE INVENTION
The inventors have realized that the effectiveness and widespread adoption of mosquito biocontrol measures, such as Wolbachia-mfected mosquitoes, can be assisted by improving the ability to store, hatch and/or raise Wolbachia-mfected mosquitoes for subsequent release into the environment.
An object of the invention is therefore to provide an improved environment for mosquito eggs. One particular object of the invention is to provide an improved nutrient environment for the storage and hatching of mosquito eggs.
In a first aspect, the invention provides a mosquito egg capsule which comprises: a closed capsule; a filler; and a plurality of mosquito eggs; wherein the filler optionally comprises a food source for the mosquito eggs when hatched.
In a second aspect, the invention provides a method of producing a mosquito egg capsule including the steps of: combining a plurality of mosquito eggs and a filler that optionally comprises a food source for the mosquito eggs when hatched; delivering at least a portion of the combined mosquito eggs and filler into one or a plurality of capsules; and closing the capsules.
This aspect also includes a mosquito egg capsule produced according to the method. In a third aspect, the invention provides a method of producing mosquitoes, including the step of introducing one or more mosquito egg capsules according to the aformentioned aspects, or mosquitoes produced therefrom, into into an environment under conditions that facilitate hatching of mosquito eggs into mosquito larvae.
The environment may be an artificial environment such as a mosquito rearing system or may be a natural environment.
In a fourth aspect, the invention provides a method of releasing mosquitoes into an environment, including the step of introducing one or more mosquito egg capsules according to the aformentioned aspects, or mosquitoes produced therefrom, into said environment under conditions that facilitate hatching of mosquito eggs into mosquito larvae.
Accordingly, in a particular aspect the invention provides a method of modifying a mosquito population, including the step of introducing a mosquito egg capsule according to the aforementioned aspect, or mosquitoes produced therefrom, into an environment under conditions that facilitate hatching of mosquito eggs into mosquito larvae, wherein release of the mosquito larvae into the environment modifies one or more biological properties of said mosquito population.
In one embodiment, the mosquitoes are wild-type or otherwise naturally- occurring mosquitoes that exist in a local environment, region or habitat.
In another embodiment, the mosquitoes have been modified for use as a biocontrol agent in said environment.
In a particular embodiment, the mosquito eggs are infected with or otherwise comprise a mosquito-adapted bacterium capable of modifying one or more biological properties of a mosquito, wherein said mosquito-adapted bacterium does not normally colonize, inhabit, reside in, or infect said mosquito host.
In an embodiment, said mosquito-adapted bacterium is of the genus Wolbachia. In another preferred embodiment, said isolated mosquito-adapted bacterium is of the species Wolbachia pipientis.
In one particularly preferred embodiment, said isolated mosquito-adapted bacterium is wMel.
Throughout this specification, unless otherwise indicated, "comprise",
"comprises" and "comprising" are used inclusively rather than exclusively, so that a stated integer or group of integers may include one or more other no n- stated integers or groups of integers.
As used herein, the indefinite articles "a" and "an" should not be read as stating or implying singularity, but instead may also mean "more than one". By way of example, "a capsule" may relate to a single capsule or a plurality of capsules.
As used herein, "about" is used to refer to a variation of tolerance in a stated amount. Typically, the variation or tolerance is no more than +10%, +9%, +8%, +7%, +6%, +5%, ±4%, +3%, +2% or +1% from a stated amount.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
The present invention is predicated on the discovery that mosquitoes may be hatched from eggs that are stored in a capsule comprising a filler that provides a suitable food source for the mosquito larvae. Accordingly a particular form of the invention relates to a capsule comprising mosquito eggs that may be used as a source of mosquitoes for biocontrol of mosquito-borne diseases. In one particular embodiment, the mosquito eggs are infected with a mosquito-adapted Wolbachia bacterium into the environment to thereby modify mosquito populations and control mosquito-borne diseases such as dengue fever.
For the purposes of this invention, by "isolated" is meant material that has been removed from its natural state or otherwise been subjected to human manipulation. Isolated material may be substantially or essentially free from components that normally accompany it in its natural state, or may be manipulated so as to be in an artificial state together with components that normally accompany it in its natural state. As used herein "mosquito " and "mosquitoes" include insects of the family Culicidae. Preferably, mosquitoes are of the sub-families Anophelinae and Culicinae. Even more preferably, mosquitoes are capable of transmitting disease- causing pathogens, including viruses, protozoa, worms {e.g. nematodes) and bacteria to a host. Non-limiting examples include species of the genus Anopheles which transmit malaria pathogens, species of the genus Culex, and species of the genus Aedes (e.g. Aedes aegypti, Aedes albopictus and Aedes polynesiensis) which transmit nematode worm pathogens, arbovirus pathogens such as Alphaviruses (e.g. Eastern Equine encephalitis, Western Equine encephalitis, Venezuelan equine encephalitis and Chikungunya virus), Flavivirus pathogens that cause diseases such as Japanese encephalitis, Murray Valley Encephalitis, West Nile fever, Yellow fever, Dengue fever and Zika virus-associated conditions such as Zika fever, microencephaly and Guillain-Barre syndrome, and Bunyavirus pathogens that cause diseases such as LaCrosse encephalitis, Rift Valley Fever, and Colorado tick fever, although without limitation thereto. Non-limiting examples of worm pathogens include nematodes (e.g. filarial nematodes such as Wuchereria bancrofti, Brugia malayi, Brugia pahangi or Brugia timori), which may be transmitted by mosquitoes.
Disease-causing pathogens transmitted by mosquitoes also include bacteria (e.g. Yersinia pestis, Borellia spp, Rickettsia spp, and Erwinia carotovora).
Non-limiting examples of pathogens that may be transmitted by Aedes aegypti are dengue virus, Zika virus, Yellow fever virus, Chikungunya virus and heartworm (Dirofilaria immitis).
Examples of pathogens that may be transmitted by Aedes albopictus include West Nile Virus, Yellow fever virus, St. Louis Encephalitis, dengue virus, Zika virus and Chikungunya virus although without limitation thereto.
Pathogens frequently transmitted by the mosquito vector Anopheles gambiae include malaria parasites of the genus Plasmodium such as, but not limited to, Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium berghei, Plasmodium gallinaceum, and Plasmodium knowlesi.
In one embodiment, said mosquito is of a genus selected from the group consisting of Culex, Aedes and Anopheles.
In a preferred embodiment, said mosquito of a species selected from the group consisting of Aedes aegypti, Aedes albopictus, and Anopheles gambiae.
In a particularly preferred embodiment, said mosquito of the species Aedes aegypti.
A "host" may be any animal upon which a mosquito feeds and/or to which a mosquito is capable of transmitting a disease-causing pathogen. Non-limiting examples of hosts are mammals such as humans, domesticated pets {e.g. dogs and cats), wild animals {e.g. monkeys, rodents and wild cats) livestock animals {e.g. sheep, pigs, cattle, and horses) and avians such as poultry {e.g. chickens, turkeys and ducks), although without limitation thereto.
As previously described, an aspect of the invention provides a mosquito egg capsule which comprises: a closed capsule; a filler; and a plurality of mosquito eggs; wherein the filler optionally comprises a food source for the mosquito eggs when hatched.
The capsule disclosed herein may be any closed or sealed container of preferably spherical, ovoid or cylindrical shape that is of suitable dimensions to encapsulate a plurality of mosquito eggs and sufficient filler to provide a food source for the mosquito eggs and/or larvae hatched therefrom. Typically, the capsule is biodegradable and has a generally flexible, pliable, colloidal or gel-like structure. Suitably, the capsule is or comprises a polymer (inclusive of copolymers), which may be of natural, semi- synthetic or synthetic origin, or a mixture thereof. The polymer may comprise protein, carbohydrates inclusive of mono-, di-, oligo- and poly- saccharides, lipids and/or other organic polymers, or mixtures of these. Non-limiting examples include gelatin, cellulosic polymers, lipid or lipid-containing encapsulating substances.
In one broad embodiment, the capsule is formed of a cellulosic polymer. Preferably, the cellulosic polymer is a polymer that is formed of glucose and/or glucose-derived monomers. Each glucose repeat unit of the polymer may comprise three (3) hydroxyl groups at least one of which may be replaced with an alkoxide to form an ether linkage. Suitably, the alkoxide is a C 1 -C 4 alkoxide. Included within the scope of the term 'C 1 -C 4 alkoxide' are substituted and unsubstituted methoxides, ethoxides, propoxides, isopropoxides, n-butoxides, sec- butoxides and tert-butoxides. The term 'substituted' refers to substitution of the relevant moiety with one or more hydroxy groups. Preferably, one or more of the three (3) hydroxyl groups of the glucose repeat unit is replaced with methoxide, ethoxide or hydro xypropoxide. Preferably, the cellulosic polymer is hydroxypropyl methyl cellulose or hydroxy ethyl methyl cellulose.
The filler may comprise a food source for the mosquito eggs. Typically, the food source comprises protein, lipids, carbohydrates, minerals, vitamins, cofactors and/or other energy and nutrient sources that are required by the mosquito eggs. Non-limiting examples of fillers include yeast and yeast extracts, fish meal (e.g. Tuna meal), plant materials such as in the form of fish flakes (e.g Veggie flakes, Tetramin) or animal material (e.g liver extracts) although without limitation thereto. Additionally or alternatively, the filler may not comprise a food source but instead comprise a bulking agent, carrier or other inert and/or non- nutritional substance that adds mass or volume to the capsule. Non-limiting examples of fillers include soluble fibres such as guar gum and psyllium husk, carnuba wax, glycerin, beta glucan, mannitol, maltitol, polydextrose, pethylcellulose and activated charcoal. In a particular embodiment a mixture of mosquito egg capsules with and without food sources may be used in combination.
Suitably, the filler is in a granular or powdered form that can be readily combined with the mosquito eggs and placed in the capsule.
Suitably, the ratio of filler to mosquito eggs is about 0.5 to 5 mg per mosquito egg, about 0.8 to 3 mg per mosquito egg or about 1 to 3 mg per mosquito egg, inclusive of about 1.1, 1.2, 1.3, 1.4, 15, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1,2.2., 2.3, 2.4 and 2.5 mg per mosquito egg.
In embodiments where the filler comprises fish meal, such as tuna meal, the fish meal is preferably about 20-80% of the filler by weight. In certain embodiments this may be about 30-70% or about 35%, 40%, 45%, 50%, 55%, 60% or 65% of the filler by weight, or any range between these stated values.
In embodiments where the filler comprises animal material, such as bovine liver powder, the animal material is preferably about 10-60% of the filler by weight. In certain embodiments, this may be about 20-50% or about 25%, 30%, 40% or 45% of the filler by weight, or any range between these stated values.
In embodiments where the filler comprises yeast or a yeast extract, this is preferably about 5-50% of the filler by weight. In certain embodiments, this may be about 10-40% or about, 12%, 15%, 20%, 25%, 30% or 35% of the filler by weight, or any range between these stated values.
It will be appreciated that the mosquito eggs and filler may be "batch- prepared" in sufficient quantity to prepare a plurality of capsules, each with substantially the same amount of mosquito eggs and filler. Preferably, each capsule comprises about 50-300 mosquito eggs, about 75-250 mosquito eggs or about 150-200 mosquito eggs. Preferably, each capsule comprises about 150-500 mg filler, about 200-400 mg filler, about 250-450 mg filler or about 285-395 mg filler.
In a particular embodiment, activated charcoal may be combined with eggs and the food source(s) in a batch preparation to prepare a mxture which is then delivered into each of a plurality of capsules. The activated charcoal acts as an inert filler that facilitates delievery of a consistent, measured amount of eggs and food source to each capsule. Preferably, each capsule will contain about 50- 200 mg of activated charcoal, about 75- 150 mg activated charcoal or about 110 mg activated charcoal.
The mosquito egg capsule disclosed herein may be suitable for storage of mosquito eggs at ambient temperature (e.g 20-25°C) with 70-90% relative humidity. Storage times may be up to 2-3 weeks under these conditions.
In one embodiment, one or a plurality of the mosquito egg capsules may be placed in an artificial mass-rearing facility for mosquitoes, particularly for the mass rearing of modified mosquitoes to be released as a biocontrol agent. Successful mass rearing of mosquitoes requires standardization of each step of the mass-rearing process. An important "first step" is mosquito egg production. Typically, mosquito eggs are placed in mass rearing trays or racks, ideally at a suitable density so that consistent numbers of eggs are hatched. This avoids overcrowding, delayed development, undersized pupae and adults and increased mortality. Furthermore, by utilizing a suitable ratio of mosquito eggs:filler, wastage of food resources can be avoided.
In a particular aspect the invention therefore provides a method of modifying a mosquito population, including the step of introducing a mosquito egg capsule into an environment (such as a natural environment) under conditions that facilitate hatching of mosquito eggs into mosquito larvae, wherein release of the mosquito larvae into the environment modifies one or more biological properties of said mosquito population.
The one or more biological properties may include fecundity, tolerance of eggs to desiccation, pathogen susceptibility, viability of offspring, average lifespan of a mosquito population and/or the ability to transmit vector-borne diseases such as, but not limited to, malaria, dengue fever, and lymphatic filariasis, although without limitation thereto.
In one particular form of the invention, the modified mosquito eggs are infected with, or otherwise comprise, a mosquito-adapted bacterium.
By "mosquito-adapted" bacterium is meant a bacterium that has been taken out of its native host environment and adapted to a mosquito host, in which environment said bacterium does not naturally reside. Accordingly, a non- limiting example of a mosquito-adapted bacterium is a Wolbachia bacterium that has been isolated from its native host (e.g. Drosophila melanogaster) and adapted to infect, colonize or reside in, a mosquito.
In a preferred embodiment, said isolated mosquito-adapted bacterium is of the genus Wolbachia.
In one particular embodiment, said isolated mosquito-adapted bacterium is Wolbachia pipientis.
Wolbachia includes strains such as wMel, wMelPop, wMelPop- CLA, vvAlbB, wAu, wMelCS, wNo, wHa, wMau and wCer2, although without limitation thereto.
Suitably, the mosquito eggs are infected with the mosquito-adapted bacterium as described in United States Patent 9090911 and in McMeniman et al., 2009, Science 323 141.
In some other embodiments, the eggs obtained by the method may be used to screen for Wolbachia infected mosquitoes to determine the spread of Wolbachia- fected mosquitoes in release areas.
In another embodiment, the eggs may be of mosquitoes for release to decrease local mosquito populations through a sterile breeding or "Sterile Insect Technique" (SIT). The sterile males may be released and compete with healthy males to mate. Matings with modified males doesn't result in offspring and the mosquito population is reduced or "crashed".
In one embodiment, the sterile insect technique (SIT) includes radiation sterilization of male mosquitoes subsequently released into the environment.
In another embodiment of SIT, mosquito biocontrol is achieved through an RNAi-based approach where an essential gene for male reproductivity is knocked out or otherwise inhibited using a small interfering RNA molecule to create "sterile males".
Another embodiment relates to a mosquito control system known as
Release of Insects with Dominant Lethality (RIDL), which is- a modified version of SIT. In this embodiment, male mosquitoes are genetically modified to contain a homozygous pair of lethal genes. One copy of these genes is passed on to offspring, so that without an antidote (e.g tetracycline), these offspring do not survive. Thus, genetically modified males compete with unmodified males to mate, resulting in no n- viable offspring and the mosquito population is reduced. By way of example, reference may be made to Massonet-Bruneel et al., 2013, PLOSOne DOI: 10.1371/journal.pone.0062711 for an example of RIDL control of dengue fever.
In a still further embodiment, the mosquito egg capsule may be used for maintaining and/or supplementing laboratory colonies of uninfected (e.g.Wolbachia free) mosquitoes.
So that the invention may be fully understood and put into practical effect, the skilled reader is directed to the following non-limiting detailed Examples.
EXAMPLES
Preparation of mosquito eggs
Mosquito eggs are initially laid by mosquitoes on a substrate such as a surface-patterned box-board substrate as originally described in International Publication WO2017/083933. After the mosquito eggs have matured and dried, they are gently brushed off from the egg substrate upon which they have been laid, using a paint brush. Brushed eggs are first sieved through a fine mesh to remove non-egg materials and then quantified by weight. Preparation of egg and filler mixture
In one example, the mosquito egg capsules are batch-prepared to achieve average constituents as follows:
1 HPMC (Hydro xypropyl Methyl Cellulose) capsule
150-200 Aedes aegypti eggs
142mg of Tuna meal
lOOmg of Bovine liver powder
43mg of brewers yeast
In this example, the food components (i.e tuna meal, bovine liver powder and yeast) are thoroughly mixed together in a separate container. A known number of mosquito eggs are then added to the food and mixed thoroughly. The egg/food mixture is then aliquoted and dispensed into individual capsules based on weight (285mg filler per HPMC capsule).
In another example, the mosquito egg capsules are batch-prepared to achieve average constituents as follows:
1 HPMC (Hydro xypropyl Methyl Cellulose) capsule 150-200 Aedes aegypti eggs
142mg of Tuna meal
lOOmg of Bovine liver powder
43mg of brewers yeast
110 mg of activated charcoal
In this example, the food components (i.e tuna meal, bovine liver powder and yeast) are thoroughly mixed together in a separate container together with activated charcoal. A known number of mosquito eggs are then added to the food and mixed thoroughly. The egg/food mixture is then aliquoted and dispensed into individual capsules based on weight (395mg filler per HPMC capsule).
Storage and use of mosquito egg capsules
The mosquito egg capsules may then be stored for up to two weeks at ambient temperatures (22°C-24°C) with 85% relative humidity maintained with a saturatated potassium chloride solution and/or water gel crytals in a closed container before being placed in a suitable environment for hatching into larvae.
As previously described, for the purposes of in vitro rearing, the mosquito eggs may be placed in mass rearing trays or racks, ideally at a suitable density so that consistent numbers of eggs are hatched. This avoids overcrowding, delayed development, undersized pupae and adults and increased mortality. Furthermore, by utilizing a suitable ratio of mosquito eggs:filler, wastage of food resources can be avoided.
Throughout this specification, the aim has been to describe the preferred embodiments of the invention without limiting the invention to any one embodiment or specific collection of features. Various changes and modifications may be made to the embodiments described and illustrated herein without departing from the broad spirit and scope of the invention.
All computer programs, algorithms, patent and scientific literature referred to herein is incorporated herein by reference in their entirety.
Next Patent: POOL STRAINER, COVER AND ASSOCIATED METHOD